Trial · NCT03132636
Adverse events276
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 276
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Group 1: Metastatic BCC (mBCC) | 6 | 54 | 9 |
| other | Nausea | Gastrointestinal disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 13 | 84 | 19 |
| other | Vomiting | Gastrointestinal disorders | Group 1: Metastatic BCC (mBCC) | 7 | 54 | 9 |
| other | Vomiting | Gastrointestinal disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 6 | 84 | 10 |
| other | Constipation | Gastrointestinal disorders | Group 1: Metastatic BCC (mBCC) | 12 | 54 | 14 |
| other | Constipation | Gastrointestinal disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 5 | 84 | 6 |
| other | Diarrhoea | Gastrointestinal disorders | Group 1: Metastatic BCC (mBCC) | 20 | 54 | 26 |
| other | Diarrhoea | Gastrointestinal disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 20 | 84 | 33 |
| other | Abdominal pain | Gastrointestinal disorders | Group 1: Metastatic BCC (mBCC) | 4 | 54 | 4 |
| other | Abdominal pain | Gastrointestinal disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 6 | 84 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Group 1: Metastatic BCC (mBCC) | 6 | 54 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 13 | 84 | 19 |
| other | Pyrexia | General disorders | Group 1: Metastatic BCC (mBCC) | 7 | 54 | 9 |
| other | Pyrexia | General disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 5 | 84 | 7 |
| other | Asthenia | General disorders | Group 1: Metastatic BCC (mBCC) | 5 | 54 | 6 |
| other | Asthenia | General disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 17 | 84 | 27 |
| other | Fatigue | General disorders | Group 1: Metastatic BCC (mBCC) | 24 | 54 | 32 |
| other | Fatigue | General disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 25 | 84 | 35 |
| other | Oedema peripheral | General disorders | Group 1: Metastatic BCC (mBCC) | 7 | 54 | 9 |
| other | Oedema peripheral | General disorders | Group 2: Unresectable Locally Advanced BCC (laBCC) | 5 | 84 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03132636/events